Lifestream Technologies receives FDA 510k clearance to market consumer cholesterol test incorporating Health Risk Assessment technology, enabling users to track cholesterol levels as well as personal risk of heart attack and obesity. Users can obtain a Health Risk Assessment profile after taking a three-minute cholesterol test and entering additional risk factors, including diabetic status, systolic and diastolic blood pressure and HDL-C break-out from a recent lipid profile. The test will be available to consumers through the firm's 1website in late June and move to other distribution channels later this year. McNeil recently announced a licensing agreement with International Medical Innovations to develop and market the PREVU(x) consumer cholesterol test (2"The Tan Sheet" June 7, 2004, p. 10)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
